ArticleBritish journal of haematology2019
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Article in British journal of haematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 53 citations in OpenAlex.
- Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial.Blood advances · 2020Trial
- IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience.Blood neoplasia · 2026Article
- Review
- Outcomes at a single institution with MTR induction and consolidation in the management of primary CNS lymphoma.Blood neoplasia · 2025Article
- Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.Blood advances · 2025Article
- Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience.Blood advances · 2025Article
- Primary Central Nervous System Lymphomas: A Single-Center Experience.Sisli Etfal Hastanesi tip bulteni · 2025Article
- Ibrutinib combined with rituximab and high-dose methotrexate in newly diagnosed primary CNS diffuse large B-cell lymphoma: a pilot study with long-term follow-up.Frontiers in oncology · 2025Article
- Novel Therapies in Primary Central Nervous System Lymphoma.Clinical pharmacology : advances and applications · 2025Review
- Both consolidation and maintenance treatment improve outcomes in primary central nervous system lymphoma: real-world evidence from a tertiary medical center.Journal of Cancer · 2025Article
- Clinical characteristics and prognosis of patients with newly diagnosed primary central nervous system lymphoma: a multicentre retrospective analysis.Annals of hematology · 2024Article
- Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.HemaSphere · 2024Article
- The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.Cancer medicine · 2024Article
- Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience.International journal of hematology · 2023Article
- Primary central nervous system lymphoma.Nature reviews. Disease primers · 2023Review
- Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.American journal of hematology · 2023Article
- Recent advances and challenges in primary central nervous system lymphoma: a narrative review.Translational cancer research · 2023Review
- Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Central Nervous System Lymphoma: Novel Therapies.Current treatment options in oncology · 2022Review
- Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.Therapeutic advances in medical oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.